株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

PharmaPoint:大腸がん - 世界の医薬品市場の予測と市場分析

PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2025

発行 GlobalData 商品コード 325931
出版日 ページ情報 英文 465 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.29円で換算しております。
Back to Top
PharmaPoint:大腸がん - 世界の医薬品市場の予測と市場分析 PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2025
出版日: 2017年01月05日 ページ情報: 英文 465 Pages
概要

大腸がん (結腸直腸がん:CRC) は、世界のがん患者の死亡原因の第2位に挙がっています。診断されたがんの中では、世界で3番目に多く、医療制度にとって莫大な負担となっています。

当レポートでは、世界の大腸がん (結腸直腸がん:CRC) の治療薬市場について調査分析し、疾患の概要とガイドライン、競合情勢、主要薬剤の詳細情報 (製品説明、安全性、有効性) 、SWOT分析、売上高予測、影響分析 (動向、促進要因・抑制要因) などについて、体系的な情報を提供しています。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要

  • 病因・病態生理
  • 臨床病期
  • 症状

第4章 疫学

  • 疾患の背景
  • 危険因子と併存疾患
  • 世界の動向
  • 予測手法
  • CRCの疫学予測
  • 議論

第5章 疾患の管理

  • 診断と治療の概要
  • 米国
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • 日本
  • 中国

第6章 競合評価

  • 概要
  • 製品プロファイル:主要ブランド

第7章 アンメットニーズと機会

  • 概要
  • 転移性患者の全生存率を実質的に高める治療
  • KRAS・BRAF変異陽性の患者に対する標的治療
  • 切除可能なハイリスク疾患に対する効果的なネオアジュバント/アジュバント療法
  • 化学療法抵抗性患者に対する許容できる後期治療

第8章 パイプライン評価

  • 概要
  • 臨床開発中の有望な薬剤
  • 開発初期段階における有望なアプローチ

第9章 現在・将来の主要企業

  • 概要
  • 企業戦略の動向
  • 企業プロファイル

第10章 市場の見通し

  • 世界市場
  • 米国
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • 日本
  • 中国

第11章 付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Colorectal Cancer (CRC) Market, considering the sales of both branded treatments and generic chemotherapy, is expected to experience a moderate growth between 2015 and 2025. The main drivers of growth will be the expected increased number of diagnosed CRC incidence, and the launch and uptake of premium-priced therapies. Traditionally, the CRC market has been dominated by two therapeutic classes: Angiogenesis and EGFR inhibitors.

It is estimated that the value of the Colorectal Cancer (CRC) market in the US, 5EU (France, Germany, Italy, Spain, and the UK), Japan, and China in 2015 was USD 8.15Billion. This market is defined as sales of generic chemotherapy and major branded drugs commonly prescribed for CRC patients across the 8MM. Just under half of these sales, USD 3.72Billion (46%), were generated in the US, with the 5EU representing the next largest region by sales, estimated at USD 2.71Billion (33%). Japan and China contributed the smallest proportion of sales to the global CRC market, with 2015 sales of USD 980Million (12%) and USD 735Million (9%), respectively.

By 2025, the end of the forecast period, projects CRC sales to rise to $10.97billion in the 8MM, at a moderate Compound Annual Growth Rate (CAGR) of 3.0%. In particular, GlobalData expects the Chinese CRC market to experience the highest growth, increasing to $1.25billion (11% total market share) by 2025, at a CAGR of 5.5%.

Major drivers of the growth of the CRC market over the forecast period include -

  • Aging populations and rising incident cases of CRC across most markets (except the US) covered in this report is responsible for the forecasted market size growth. Overall, across the 8MM, the incidence of CRC is expected to increase by an Annual Growth Rate (AGR) of 2.2% from 2015-2025.
  • The launch and uptake of premium-priced therapies will drive the growth in the CRC market.
  • It is expected that the branded drugs to facilitate the gradual increase in the number of patients receiving branded therapy across different lines of metastatic therapy, thus increasing the patient pool of these segments and the overall CRC market size.

The report "PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2025" provides an overview of CRC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

It also provides the following -

  • Annualized CRC therapeutics market revenue, cost of therapy, and treatment usage pattern data in 8 patient segments, forecast from 2015 to 2025.
  • Provides strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the CRC therapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global CRC therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Companies mentioned this report: AB Science, Amgen, Array BioPharma, AstraZeneca, Bayer, Biocad, Boehringer Ingelheim, Bristol-Myers Squibb, BTG International, Daiichi-Sankyo, Cleveland Biolabs, Eli Lilly, GlaxoSmithKline, Gradalis, Hutchinson Medi Pharma, Immunomedics, Immunovative Therapies, Jiangsu Hengrui, Merck KGaA, Merck & Co., Merrimack, Mologen, Novartis, PsiOxus therapeutics, Roche/Genentech, Sanofi, Sorrento, Sirtex, Sumitomo Dainippon Pharma, Suzhou Zelgen, Symphogen, Taiho Pharmaceuticals, Takeda, Tracon Pharmaceuticals.

Scope

  • Overview of CRC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized CRC therapeutics market revenue, cost of therapy, and treatment usage pattern data in 8 patient segments, forecast from 2015 to 2025.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the CRC therapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global CRC therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global CRC therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global CRC therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global CRC therapeutics market from 2015-2025.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1 Table of Contents

1 Table of Contents 9

  • 1.1 List of Tables 16
  • 1.2 List of Figures 22

2 Introduction 25

  • 2.1 Catalyst 25
  • 2.2 Related Reports 26
  • 2.3 Upcoming Related Reports 26

3 Disease Overview 27

  • 3.1 Etiology and Pathophysiology 27
    • 3.1.1 Etiology 27
    • 3.1.2 Pathophysiology 28
    • 3.1.3 Biomarkers/ Targets of interest 29
  • 3.2 Clinical Staging 32
  • 3.3 Symptoms 34
  • 3.4 Prognosis 34
  • 3.5 Quality of Life 35

4 Epidemiology 37

  • 4.1 Disease Background 37
  • 4.2 Risk Factors and Comorbidities 37
  • 4.3 Global Trends 39
    • 4.3.1 8MM Incidence Trends 39
    • 4.3.2 8MM, Trends in Five-Year Relative Survival 42
  • 4.4 Forecast Methodology 43
    • 4.4.1 Sources Used Tables 44
    • 4.4.2 Forecast Assumptions and Methods 48
    • 4.4.3 Sources Not Used 56
  • 4.5 Epidemiological Forecast for CRC (2015-2025) 56
    • 4.5.1 Diagnosed Incident Cases of CRC 56
    • 4.5.2 Age-Specific Diagnosed Incident Cases of CRC 58
    • 4.5.3 Sex-Specific Diagnosed Incident Cases of CRC 60
    • 4.5.4 Age-Standardized Diagnosed Incidence of CRC 62
    • 4.5.5 Diagnosed Incident Cases of CRC by Stage at Diagnosis 63
    • 4.5.6 Type of Genetic Mutation among Diagnosed Incident Cases of CRC 64
    • 4.5.7 Five-Year Diagnosed Prevalent Cases of CRC 65
  • 4.6 Discussion 67
    • 4.6.1 Epidemiological Forecast Insight 67
    • 4.6.2 Limitations of the Analysis 69
    • 4.6.3 Strengths of the Analysis 70

5 Disease Management 71

  • 5.1 Diagnosis and Treatment Overview 71
    • 5.1.1 Screening and Diagnosis 71
    • 5.1.2 Treatment Guidelines and Leading Prescribed Drugs 77
    • 5.1.3 Clinical Practice 81
  • 5.2 US 97
    • 5.2.1 Screening and Diagnosis 98
    • 5.2.2 Clinical Practice 100
  • 5.3 France 102
    • 5.3.1 Screening and Diagnosis 103
    • 5.3.2 Clinical Practice 104
  • 5.4 Germany 106
    • 5.4.1 Screening and Diagnosis 107
    • 5.4.2 Clinical Practice 108
  • 5.5 Italy 110
    • 5.5.1 Screening and Diagnosis 111
    • 5.5.2 Clinical Practice 112
  • 5.6 Spain 114
    • 5.6.1 Screening and Diagnosis 115
    • 5.6.2 Clinical Practice 116
  • 5.7 UK 118
    • 5.7.1 Screening and Diagnosis 119
    • 5.7.2 Clinical Practice 120
  • 5.8 Japan 122
    • 5.8.1 Screening and Diagnosis 123
    • 5.8.2 Clinical Practice 124
  • 5.9 China 126
    • 5.9.1 Screening and Diagnosis 128
    • 5.9.2 Clinical Practice 129

6 Competitive Assessment 131

  • 6.1 Overview 131
  • 6.2 Anti-angiogenesis drugs 132
    • 6.2.1 Avastin (Bevacizumab) 134
    • 6.2.2 Zaltrap (Ziv-Aflibercept) 146
    • 6.2.3 Cyramza (Ramucirumab) 152
  • 6.3 EGFR Targeted-therapies 157
    • 6.3.1 Erbitux (Cetuximab) 159
    • 6.3.2 Vectibix (Panitumumab) 168
  • 6.4 Kinase Inhibitors 177
    • 6.4.1 Stivarga (Regorafenib) 177
  • 6.5 Chemotherapy 185
    • 6.5.1 Lonsurf (Trifluridine + Tipiracil) 185
    • 6.5.2 TS-1 (Tegafur + Gimeracil + Oteracil) 194

7 Unmet Need and Opportunity 199

  • 7.1 Overview 199
  • 7.2 Understanding and Overcoming Mechanisms of Resistance to Angionesis and EGFR Inhibitors 201
    • 7.2.1 Unmet Need 201
    • 7.2.2 Gap Analysis 203
    • 7.2.3 Opportunity 204
  • 7.3 Targeted Treatments for BRAF Mutation-Positive Patients 205
    • 7.3.1 Unmet Need 205
    • 7.3.2 Gap Analysis 206
    • 7.3.3 Opportunity 206
  • 7.4 Extending the Use of Immunotherapies to the MSS Population 207
    • 7.4.1 Unmet Need 207
    • 7.4.2 Gap Analysis 208
    • 7.4.3 Opportunity 209
  • 7.5 Effective Neoadjuvant/Adjuvant Therapies for High Risk Resectable Disease 210
    • 7.5.1 Unmet Need 210
    • 7.5.2 Gap Analysis 211
    • 7.5.3 Opportunity 212
  • 7.6 Identification of Positive Predictive Biomarkers 213
    • 7.6.1 Unmet Need 213
    • 7.6.2 Gap Analysis 214
    • 7.6.3 Opportunity 214
  • 7.7 Additional and More Effective Later-Line Therapies for Chemotherapy-Resistant Patients 215
    • 7.7.1 Unmet Need 215
    • 7.7.2 Gap Analysis 216
    • 7.7.3 Opportunity 217

8 Pipeline Assessment 218

  • 8.1 Overview 218
  • 8.2 Promising Drugs in Clinical Development 220
  • 8.3 Immunotherapies 221
    • 8.3.1 Lefitolimod (MGN-1703) 222
    • 8.3.2 Keytruda (pembrolizumab) 229
    • 8.3.3 Tecentriq (atezolizumab) 237
  • 8.4 Molecular-Targeted Agents 245
    • 8.4.1 Encorafenib (LGX-818) + Binimetinib (MEK-162) 245
    • 8.4.2 Napabucasin (BBI-608) 254
    • 8.4.3 Vargatef (Nintedanib) 261
    • 8.4.4 Masitinib (AB-1010) 266
    • 8.4.5 Fruquintinib (HMPL-013) 271
    • 8.4.6 Famitinib (SHR-1020) 277
    • 8.4.7 Donafenib (CM-4307) 282
  • 8.5 Promising Approaches in Early Stage Development 285
    • 8.5.1 Strategies to Overcome VEGF-Resistance 285
    • 8.5.2 Strategies for BRAF Mutation-Positive Disease 288
    • 8.5.3 Strategies for RAS-Mutation Positive Disease 293
    • 8.5.4 Strategies to Overcome EGFR-Acquired Resistance 297
    • 8.5.5 Immune Checkpoint Inhibitors Combinations 300
    • 8.5.6 Other Strategies 304
    • 8.5.7 Liver Directed Therapies 308
  • 8.6 Biosimilars 311
    • 8.6.1 Bevacizumab Biosimilars 314
    • 8.6.2 Cetuximab Biosimilars 316

9 Current and Future Players 317

  • 9.1 Overview 317
  • 9.2 Trends in Corporate Strategy 321
  • 9.3 Company Profiles 322
    • 9.3.1 Amgen 322
    • 9.3.2 Bayer 325
    • 9.3.3 Eli Lilly and Company 328
    • 9.3.4 Merck KGaA 331
    • 9.3.5 Merck & Co. 333
    • 9.3.6 Roche/Genentech 335
    • 9.3.7 Taiho Pharmaceutical 339

10 Market Outlook 343

  • 10.1 Global Markets 343
    • 10.1.1 Forecast 343
    • 10.1.2 Drivers and Barriers - Global Issues 346
  • 10.2 United States 349
    • 10.2.1 Forecast 349
    • 10.2.2 Key Events 353
    • 10.2.3 Drivers and Barriers 353
  • 10.3 5 EU 356
    • 10.3.1 Forecast 356
    • 10.3.2 Key Events 359
    • 10.3.3 Drivers and Barriers 359
  • 10.4 Japan 362
    • 10.4.1 Forecast 362
    • 10.4.2 Key Events 365
    • 10.4.3 Drivers and Barriers 365
  • 10.5 China 368
    • 10.5.1 Forecast 368
    • 10.5.2 Key Events 371
    • 10.5.3 Drivers and Barriers 371

11 Appendix 376

  • 11.1 Bibliography 376
  • 11.2 Abbreviations 431
  • 11.3 Methodology 439
  • 11.4 Forecasting Methodology 439
    • 11.4.1 Diagnosed CRC Patients 440
    • 11.4.2 Percent Drug-Treated Patients 441
    • 11.4.3 Drugs Included in Each Therapeutic Class 441
    • 11.4.4 Launch and Patent Expiry Dates 442
    • 11.4.5 General Pricing Assumptions 443
    • 11.4.6 Individual Drug Assumptions 445
    • 11.4.7 Generic Erosion 453
    • 11.4.8 Pricing of Pipeline Agents 454
  • 11.5 Primary Research - KOLs Interviewed for this Report 456
  • 11.6 Primary Research - Prescriber Survey 459
  • 11.7 About the Authors 459
    • 11.7.1 Analyst 459
    • 11.7.2 Reviewers 460
    • 11.7.3 Therapy Area Director 460
    • 11.7.4 Epidemiologist 461
    • 11.7.5 Reviewers 461
    • 11.7.6 Global Head of Healthcare 463
  • 11.8 About GlobalData 463
  • 11.9 Disclaimer 464

List of Tables

1.1 List of Tables

  • Table 1: Stage Definitions for Colorectal Cancer 33
  • Table 2: Symptoms of CRC 34
  • Table 3: Prognosis for Colon and Rectal Cancer 35
  • Table 4: Risk Factors and Comorbidities For CRC 38
  • Table 5: 8MM, Five-Year Relative Survival (%) 43
  • Table 6: 8MM, Sources Used to Forecast the Diagnosed Incidence of CRC 44
  • Table 7: 8MM, Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases of CRC 45
  • Table 8: 8MM, Sources of CRC Cancer Stage at Diagnosis 45
  • Table 9: 8MM, Sources of Genetic Mutations 47
  • Table 10: 8MM, Diagnosed Incident Cases of CRC (N), Both Sexes, Ages ≥18 Years, 2015-2025 58
  • Table 11: 8MM, Age-Specific Diagnosed Incident Cases of CRC (N), Both Sexes, Row (%), 2015 59
  • Table 12: 8MM, Sex-Specific Diagnosed Incident Cases of CRC (N), Ages ≥18 Years, Row (%), 2015 61
  • Table 13: 8MM, Diagnosed Incident Cases of CRC by Cancer Stage at Diagnosis (N), Ages ≥18 Years, Row (%), 2015 64
  • Table 14: 8MM, Diagnosed Incident Cases of CRC by Type of Genetic Mutation (N), Both Sexes, Ages ≥18 Years, 2015 65
  • Table 15: 8MM, Five-Year Diagnosed Prevalent Cases of CRC (N), Both Sexes, Ages ≥18 Years, 2015-2025 66
  • Table 16: Treatment Guidelines for CRC 77
  • Table 17: Most Prescribed Neoadjuvant/Adjuvant Regimens for Early-Stage Colon and Rectal Cancer in the 8MM, 2016 78
  • Table 18: Most Prescribed Targeted Therapies for mCRC, by Segment in the 8MM, 2016 79
  • Table 19: Country Profile - US 97
  • Table 20: Country Profile - France 102
  • Table 21: Country Profile - Germany 106
  • Table 22: Country Profile - Italy 110
  • Table 23: Country Profile - Spain 114
  • Table 24: Country Profile - UK 118
  • Table 25: Country Profile - Japan 122
  • Table 26: Country Profile - China 127
  • Table 27: Leading Treatments for CRC, 2016 132
  • Table 28: Product Profile - Avastin 135
  • Table 29: Summary of the Results from the AVF2107 Trial of Avastin Plus IFL 139
  • Table 30: Summary of the Results from the CALGB 80405 and FIRE-3 Trials of Avastin/Erbitux plus Chemotherapy 141
  • Table 31: Summary of the Results of the ML18147 Study 142
  • Table 32: Summary of the Results from the E3200 Trial of Avastin Plus FOLFOX 142
  • Table 33: Summary of AEs from the AVF21070 trial of Avastin 144
  • Table 34: Avastin SWOT Analysis, 2016 145
  • Table 35: Product Profile - Zaltrap 147
  • Table 36: Summary of the Results from the VELOUR Study 150
  • Table 37: Summary of Frequent Grade 3 and 4 AEs from the VELOUR trial of Zaltrap 151
  • Table 38: Zaltrap SWOT Analysis, 2016 152
  • Table 39: Product Profile - Cyramza 153
  • Table 40: Summary of the Phase III RAISE Trial of Cyramza 155
  • Table 41: Summary of Frequent Grade 3 and 4 AEs in a Phase III Trial for Cyramza 156
  • Table 42: Cyramza SWOT Analysis, 2016 157
  • Table 43: Product Profile - Erbitux 160
  • Table 44: Summary of the Result of the CRYSTAL Study 163
  • Table 45: Summary of the Results of the CRYSTAL Study - BRAF Mutation 164
  • Table 46: Retrospective Analysis of CRYSTAL and FIRE-3 Studies of Erbitux 165
  • Table 47: Summary of Frequent AEs from the CRYSTAL Trial of Erbitux 166
  • Table 48: Erbitux SWOT Analysis, 2016 167
  • Table 49: Product Profile - Vectibix 168
  • Table 50: Summary of the Results from the PRIME Trial of Vectibix 172
  • Table 51: Summary of the Results from the PEAK Study of Vectibix 173
  • Table 52: Summary of the Results from the Phase III Study of Vectibix as Monotherapy 174
  • Table 53: Summary of the Results from the ASPECCT Study of Vectibix 174
  • Table 54: Incidence of Grade 3-4 AEs of the PRIME Trial of Vectibix 175
  • Table 55: Vectibix SWOT Analysis, 2016 176
  • Table 56: Product Profile - Stivarga 177
  • Table 57: Summary of the Results from the CORRECT Study of Stivarga 181
  • Table 58: Summary of Frequent Grade 3 and 4 AEs from the CORRECT Trial of Stivarga 183
  • Table 59: Stivarga SWOT Analysis, 2016 184
  • Table 60: Product Profile - Lonsurf 186
  • Table 61: Summary of the Phase III RECOURSE Trial of Lonsurf 190
  • Table 62: Summary of the AEs in the Phase III Trial of Lonsurf 192
  • Table 63: Lonsurf SWOT Analysis, 2016 193
  • Table 64: Product Profile - TS-1 194
  • Table 65: Summary of a Phase III trial of TS-1 196

Table 66 Summary of Most Common AEs in a Phase III Trial of TS-1 197

  • Table 67: TS-1 SWOT Analysis, 2016 198
  • Table 68: Unmet Needs and Opportunities in CRC 201
  • Table 69: Product Profile - Lefitolimod 222
  • Table 70: Summary of the IMPACT Trial of Lefitolimod 225
  • Table 71: Summary of the Most Common AEs Reported in the IMPACT Trial of Lefitolimod 226
  • Table 72: Lefitolimod SWOT Analysis, 2016 228
  • Table 73: Product Profile - Keytruda 229

Table 74 Summary of the Results of the Phase II Trial of Keytruda 233

  • Table 75: Summary of Frequent AEs in the Phase II Trial of Keytruda 234
  • Table 76: Keytruda SWOT analysis, 2016 236
  • Table 77: Product Profile - Tecentriq 237
  • Table 78: Summary of the Phase Ib Trial of Tecentriq 241
  • Table 79: Summary of Frequent AEs in the Phase Ib Trial of Tecentriq 242
  • Table 80: Tecentriq SWOT analysis, 2016 244
  • Table 81: Product Profile - Encorafenib +Binimetinib 245
  • Table 82: Summary of the Results from the Phase II Trial of Encorafenib 249
  • Table 83: Summary of Frequent AEs in the Phase II Trial of Encorafenib 251
  • Table 84: Encorafenib + binimetinib - SWOT Table, 2016 253
  • Table 85: Product Profile - Napabucasin 254
  • Table 86: Summary of the Result from the Phase Ib Trial of Napabucasin 257
  • Table 87: Summary of the Result from the Phase II Trial Investigating Napabucasin + Vectibix 258
  • Table 88: Napabucasin, SWOT Analysis, 2016 260
  • Table 89: Product Profile - Vargatef 261
  • Table 90: Summary of the Result of the Phase III LUME Colon-1 Trial of Vargatef 264
  • Table 91: Vargatef SWOT Analysis, 2016 265
  • Table 92: Product Profile - Masitinib 266
  • Table 93: Summary of the Results of the Phase II Trial of Masitinib 269
  • Table 94: Masitinib SWOT Analysis, 2016 271
  • Table 95: Product Profile - Fruquintinib 272
  • Table 96: Summary of the Results of the Phase II Trial of Fruquintinib 274
  • Table 97: Summary of Frequent AEs in the Phase II trial of Fruquintinib 275
  • Table 98: Fruquintinib SWOT Analysis, 2016 277
  • Table 99: Product Profile - Famitinib 278
  • Table 100: Summary of the Results of the Phase II Trial of Famitinib 280
  • Table 101: Summary of Frequent AEs in a Phase II trial of Famitinib 280
  • Table 102: Famitinib SWOT Analysis, 2016 282
  • Table 103: Product Profile - Donafenib 283
  • Table 104: Donafenib SWOT Analysis, 2016 285
  • Table 105: Promising strategies to overcome VEGF resistance 286
  • Table 106: Early-stage Strategies for BRAF Mutation-Positive CRC 290
  • Table 107: Early-stage Strategies for KRAS Mutation-Positive CRC 295
  • Table 108: Early-Stage Strategies for EGFR Acquired Resistance 298
  • Table 109: Anti-PD1 and Anti-PDL1 Drugs in Early-Stage Development for CRC 302
  • Table 110: CAR-T Cell Therapies Under Development 305
  • Table 111: Vaccines in Development in CRC 307
  • Table 112: Radioembolization Tecnhiquese Evaluated for the Treatment of Colorectal Cancer Liver Metastasis 309
  • Table 113: List of Bevacizumab Biosimilars in Phase III Development 314
  • Table 114: Key Companies in the CRC Market in the 8MM, 2015-2025 319
  • Table 115: Amgen's CRC Portfolio Assessment, 2016 324
  • Table 116: Bayer's CRC Portfolio Assessment, 2016 327
  • Table 117: Eli Lilly's CRC Portfolio Assessment, 2016 330
  • Table 118: Merck KGaA's CRC Portfolio Assessment, 2016 332
  • Table 119: Merck & Co.'s CRC Portfolio Assessment, 2016 335
  • Table 120: Roche's CRC Portfolio Assessment, 2016 338
  • Table 121: Taiho's CRC Portfolio Assessment, 2016 341
  • Table 122: CRC Market Drivers and Barriers, 2016 346
  • Table 123: Key Events Impacting Sales for CRC in the US, 2015-2025 353
  • Table 124: US CRC Market Drivers and Barriers, 2016 353
  • Table 125: Key Events Impacting Sales for CRC in the 5EU, 2015-2025 359
  • Table 126: 5EU CRC Market Drivers and Barriers, 2016 359
  • Table 127: Key Events Impacting Sales for CRC in Japan, 2015-2025 365
  • Table 128: Japan CRC Market - Drivers and Barriers, 2016 365
  • Table 129: Key Events Impacting Sales for CRC in China, 2015-2025 371
  • Table 130: China CRC Market - Drivers and Barriers, 2016 371
  • Table 131: Key Historical and Projected Launch Dates for Colorectal Cancer 442
  • Table 132: Key Historical and Projected Patent Expiry Dates for Colorectal Cancer 443

Table 133 Average Body Weight and Surface Area Across the 8MM 445

  • Table 134: Treatment Duration in Colorectal Cancer 445
  • Table 135: Average Cost of Therapy of Avastin in the 8MM 446
  • Table 136: Average Cost per Cycle of Chemotherapy Regimens in the 8MM 448
  • Table 137: Average Cost of Therapy of Cyramza in the 8MM (excluding urban China) 449
  • Table 138: Average Cost of Therapy of Erbitux in the 8MM 450
  • Table 139: Average Cost of Therapy of Lonsurf in the 8MM 451
  • Table 140: Average Cost of Therapy of Stivarga in the 8MM 452
  • Table 141: Average Cost of Therapy of Vectibix in the 8MM 452
  • Table 142: Average Cost of Therapy of Zaltrap in the US and 5EU 453
  • Table 143: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 459

List of Figures

1.2 List of Figures

  • Figure 1: 8MM, Age-Adjusted Incidence Rate for CRC (Cases per 100,000 Population), Men, Ages ≥15 Years, 1998-2007 41
  • Figure 2: 8MM, Age-Adjusted Incidence Rate for CRC (Cases per 100,000 Population), Women, Ages ≥15 Years, 1998-2007 42
  • Figure 3: 8MM, Diagnosed Incident Cases of CRC (N), Both Sexes, Ages ≥18 Years, 2015-2025 58
  • Figure 4: 8MM, Age-Specific Diagnosed Incident Cases of CRC (N), Both Sexes, Ages ≥18 Years, 2015 60
  • Figure 5: 8MM, Sex-Specific Diagnosed Incident Cases of CRC (N), Ages ≥18 Years, 2015 62
  • Figure 6: 8MM, Age-Standardized Incidence of CRC (Cases per 100,000 Population), Ages ≥18 Years, by Sex, 2015. 63
  • Figure 7: 8MM, Five-Year Diagnosed Prevalent Cases of CRC (N), Both Sexes, Ages ≥18 Years, 2015-2025 66
  • Figure 8: Treatment Flowchart for Regional or Locoregional CRC 84
  • Figure 9: Treatment Flowchart for mCRC 88
  • Figure 10: The Zurich Treatment Algorithm 92
  • Figure 11: Avastin's Development in CRC 138
  • Figure 12: Cyramza's Development in CRC 155
  • Figure 13: Erbitux's Development in CRC 162
  • Figure 14: Vectibix Development in CRC 171
  • Figure 15: Stivarga's Development in CRC 181
  • Figure 16: Lonsurf's Development in CRC 189
  • Figure 17: TS-1 Development in CRC 196
  • Figure 18: CRC - Phase III Pipeline, 2016 220
  • Figure 19: Competitive Assessment of Late-Stage Pipeline Agents in CRC, 2015-2025 221
  • Figure 20: Lefitolimod's Clinical Development in CRC 224
  • Figure 21: Clinical and Commercial Positioning of Lefitolimod 227
  • Figure 22: Keytruda's Clinical Development in CRC 232
  • Figure 23: Clinical and Commercial Positioning of Keytruda 235
  • Figure 24: Tecentriq's Clinical Development in CRC 240
  • Figure 25: Clinical and Commercial Positioning of Tecentriq 243
  • Figure 26: Encorafenib's Clinical Development in CRC 249
  • Figure 27: Potential Clinical and Commercial Positioning for Encorafenib + BInimetinib 252
  • Figure 28: Napabucasin's Clinical Development in CRC 257
  • Figure 29: Clinical and Commercial Positioning of Napabucasin 259
  • Figure 30: Vargatef's Clinical Development in CRC 263
  • Figure 31: Clinical and Commercial Positioning of Vargatef 265
  • Figure 32:Masitinib's Clinical Development in CRC 268
  • Figure 33: Clinical and Commercial Positioning of Masitinib 270
  • Figure 34: Fruquintinib's Clinical Development in CRC 274
  • Figure 35: Clinical and Commercial Positioning of Fruquintinib 276
  • Figure 36: Famitinib's Clinical Development in CRC 279
  • Figure 37: Clinical and Commercial Positioning of Famitinib 281
  • Figure 38: Donafenib's Clinical Development in CRC 284
  • Figure 39: Clinical and Commercial Positioning of Donafenib 284
  • Figure 40: Clinical Development of Bevacizumab Biosimilars 315
  • Figure 41: Global Sales of Branded Products for CRC by Company, 2015-2025 320
  • Figure 42: Company Portfolio Gap Analysis in CRC, 2015-2025 321
  • Figure 43: Amgen SWOT Analysis in CRC, 2016 325
  • Figure 44: Bayer SWOT Analysis in CRC, 2016 327
  • Figure 45: Eli Lilly SWOT Analysis in CRC, 2016 330
  • Figure 46: Merck KGaA SWOT Analysis in CRC, 2016 333
  • Figure 47: Merck & Co. SWOT Analysis in CRC, 2016 335
  • Figure 48: Roche SWOT Analysis in CRC, 2016 339
  • Figure 49: Taiho SWOT Analysis in CRC, 2016 342
  • Figure 50: Global Sales for CRC by Region, 2015-2025 345
  • Figure 51: Global Sales for CRC by Drug Class, 2015-2025 346
  • Figure 52: Sales for CRC in the US, by Drug Class, 2015-2025 352
  • Figure 53: Sales for CRC in the 5EU, by Drug Class, 2015-2025 358
  • Figure 54: Sales for CRC in Japan, by Drug Class, 2015-2025 364
  • Figure 55: Sales for CRC in China by Drug Class, 2015-2025 370
Back to Top